BofA analyst David Li raised the firm’s price target on BeiGene to $263.30 from $230.10 and keeps a Neutral rating on the shares. It was announced on April 6 that the accelerated approval of Ibrutinib for the treatment of MCL and MZL would be withdrawn and given this news the firm expects zanubrutinib could grab more market share in MCL and MZL market, leading it to lift its sales forecast for its MCL/MZL indications in both the China and U.S. market.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BGNE:
- Enlivex Therapeutics provides business updates on clinical programs
- Enlivex, BeiGene collaborate to evaluate Allocetra with Tislelizumab
- J.P. Morgan Analysts Say These 2 Stocks Are Their Top Picks for 2023
- 5 Best Healthcare Stocks to Invest in Now, According to Analysts
- BeiGene enters new phase to expand U.S. R&D capacity in NJ
